ASCO: Cilta-Cel Beneficial for Lenalidomide-Refractory Multiple Myeloma

Single cilta-cel infusion results in lower risk of disease progression or death compared with standard care

multiple myeloma
Adobe Stock

THURSDAY, June 8, 2023 (HealthDay News) -- For patients with lenalidomide-refractory multiple myeloma, a single cilta-cel infusion results in lower risk of disease progression or death compared with standard care, according to a study published online June 5 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 2 to 6 in Chicago.

Jesús San-Miguel, M.D., Ph.D., from the Cancer Center Clínica Universidad de Navarra in Spain, and colleagues conducted a phase 3 randomized trial involving patients with lenalidomide-refractory multiple myeloma who had received one to three previous lines of treatment. A total of 419 patients were randomly assigned to cilta-cel or standard care (208 and 211, respectively).

The researchers found that the median progression-free survival was not reached in the cilta-cel group and was 11.8 months in the standard care-group at a median follow-up of 15.9 months (hazard ratio, 0.26). At 12 months, progression-free survival was 75.9 and 48.6 percent in the cilta-cel and standard-care groups, respectively. Compared with patients in the standard-care group, more patients in the cilta-cel group had an overall response (84.6 versus 67.3 percent), a complete response or better (73.1 versus 21.8 percent), and an absence of minimal residual disease (60.6 versus 15.6 percent).

"The strong progression-free survival benefit and rapid and deep response with cilta-cel highlight the potential for cilta-cel to become a therapeutic option for patients with myeloma after the first relapse," the authors write.

The study was funded by Janssen Research and Development and Legend Biotech USA.

Abstract/Full Text (subscription or payment may be required)

More Information

Elana Gotkine

Elana Gotkine

Medically reviewed by Mark Arredondo, M.D.

Published on June 08, 2023

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ